Moderate hypofractionated helical tomotherapy for older patients with localized prostate cancer: long-term outcomes of a phase I–II trial

Abstract

Our previous study showed that two different regimens of moderate hypofractionated radiotherapy (HFRT) delivered with helical tomotherapy (HT) are well tolerated in older prostate cancer patients. We provide a longterm efficacy and toxicity after > 7 years of follow-up.

Keywords

• helical tomotherapy
• radiation dose hypofractionation
• progression-free survival
• follow-up studies
• prostatic neoplasms
• adenocarcinoma